{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:51:19Z","timestamp":1769176279615,"version":"3.49.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["RP-PG-0407-10177"],"award-info":[{"award-number":["RP-PG-0407-10177"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.K. Dermatology Clinical Trials Network (DCTN)"},{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1111\/bjd.15561","type":"journal-article","created":{"date-parts":[[2017,4,9]],"date-time":"2017-04-09T09:06:53Z","timestamp":1491728813000},"page":"1527-1536","source":"Crossref","is-referenced-by-count":25,"title":["Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial"],"prefix":"10.1093","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-4082","authenticated-orcid":false,"given":"J.M.","family":"Mason","sequence":"first","affiliation":[{"name":"Warwick Medical School; University of Warwick; Coventry CV4 7AL U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-7465","authenticated-orcid":false,"given":"K.S.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; NG7 2NR U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Ormerod","sequence":"additional","affiliation":[{"name":"Division of Applied Medicine; Aberdeen University; Aberdeen AB24 2ZD U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.E.","family":"Craig","sequence":"additional","affiliation":[{"name":"Department of Dermatology; NHS Forth Valley; Stirling FK8 2AU U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit; University of Nottingham; Nottingham NG7 2UH U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Norrie","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit; Usher Institute; University of Edinburgh; EH16 4TU U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; NG7 2NR U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the U.K. Dermatology Clinical Trials Network's STOP GAP team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"10.1111\/bjd.15561-BIB0001|bjd15561-cit-0001","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.333.7560.181","article-title":"Diagnosis and treatment of pyoderma gangrenosum","volume":"333","author":"Brooklyn","year":"2006","journal-title":"BMJ"},{"key":"10.1111\/bjd.15561-BIB0002|bjd15561-cit-0002","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15561-BIB0003|bjd15561-cit-0003","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.15561-BIB0004|bjd15561-cit-0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00105-009-1909-8","article-title":"Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy","volume":"61","author":"Tremezaygues","year":"2010","journal-title":"Hautarzt"},{"key":"10.1111\/bjd.15561-BIB0005|bjd15561-cit-0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bjps.2014.12.036","article-title":"A systematic review of post-surgical pyoderma gangrenosum: identification of risk factors and proposed management strategy","volume":"68","author":"Zuo","year":"2015","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1111\/bjd.15561-BIB0006|bjd15561-cit-0006","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.15561-BIB0007|bjd15561-cit-0007","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2009.05.030","article-title":"Pyoderma gangrenosum: a review and update on new therapies","volume":"62","author":"Miller","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15561-BIB0008|bjd15561-cit-0008","unstructured":"British Association of Dermatologists Patient information leaflet on pyoderma gangrenosum http:\/\/www.bad.org.uk\/for-the-public\/patient-information-leaflets\/pyoderma-gangrenosum"},{"key":"10.1111\/bjd.15561-BIB0009|bjd15561-cit-0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","article-title":"Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients","volume":"53","author":"Reichrath","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15561-BIB0010|bjd15561-cit-0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1111\/bjd.15561-BIB0011|bjd15561-cit-0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1745-6215-13-51","article-title":"UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial","volume":"13","author":"Craig","year":"2012","journal-title":"Trials"},{"key":"10.1111\/bjd.15561-BIB0012|bjd15561-cit-0012","doi-asserted-by":"crossref","first-page":"h2958","DOI":"10.1136\/bmj.h2958","article-title":"UK Dermatology Clinical Trials Network's STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"key":"10.1111\/bjd.15561-BIB0013|bjd15561-cit-0013","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"10.1111\/bjd.15561-BIB0014|bjd15561-cit-0014","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","article-title":"Variations in population health status: results from a United Kingdom national questionnaire survey","volume":"316","author":"Kind","year":"1998","journal-title":"BMJ"},{"key":"10.1111\/bjd.15561-BIB0015|bjd15561-cit-0015","unstructured":"Dolan P Gudex C Kind P Williams A A Social Tariff for EuroQol: Results from a UK general population survey http:\/\/www.york.ac.uk\/media\/che\/documents\/papers\/discussionpapers\/CHE%20Discussion%20Paper%20138.pdf"},{"key":"10.1111\/bjd.15561-BIB0016|bjd15561-cit-0016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N","article-title":"The time trade-off method: results from a general population survey","volume":"5","author":"Dolan","year":"1996","journal-title":"Health Econ"},{"key":"10.1111\/bjd.15561-BIB0017|bjd15561-cit-0017","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.15561-BIB0018|bjd15561-cit-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3100","article-title":"Methods for the analysis of quality-of-life and survival data in health technology assessment","volume":"3","author":"Billingham","year":"1999","journal-title":"Health Technol Assess"},{"key":"10.1111\/bjd.15561-BIB0019|bjd15561-cit-0019","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"10.1111\/bjd.15561-BIB0020|bjd15561-cit-0020","unstructured":"NHS Prescription Services Prescription Cost Analysis (PCA) Data, England 2012 http:\/\/content.digital.nhs.uk\/catalogue\/PUB10610"},{"key":"10.1111\/bjd.15561-BIB0021|bjd15561-cit-0021","unstructured":"Department of Health Reference Cost Collection: National schedule of reference costs - year 2011-12 - NHS trusts and NHS foundation trusts https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-financial-year-2011-to-2012"},{"key":"10.1111\/bjd.15561-BIB0022|bjd15561-cit-0022","unstructured":"NHS Digital Hospital Episode Statistics, Admitted Patient Care - England, 2011-12 http:\/\/content.digital.nhs.uk\/catalogue\/PUB08288"},{"key":"10.1111\/bjd.15561-BIB0023|bjd15561-cit-0023","volume-title":"DRG Desk Reference (ICD-10-CM) 2015","author":"Krawzik","year":"2015"},{"key":"10.1111\/bjd.15561-BIB0024|bjd15561-cit-0024","unstructured":"Curtis L Unit Costs of Health and Social Care 2012 Canterbury, U.K University of Kent 2012 http:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/2012"},{"key":"10.1111\/bjd.15561-BIB0025|bjd15561-cit-0025","unstructured":"Curtis L Burns A Unit Costs of Health and Social Care 2016 Canterbury, U.K University of Kent 2016 http:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/2016"},{"key":"10.1111\/bjd.15561-BIB0026|bjd15561-cit-0026","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/bjd.15561-BIB0027|bjd15561-cit-0027","doi-asserted-by":"crossref","first-page":"d40","DOI":"10.1136\/bmj.d40","article-title":"Strategy for intention to treat analysis in randomised trials with missing outcome data","volume":"342","author":"White","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/bjd.15561-BIB0028|bjd15561-cit-0028","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/bjd.15561-BIB0029|bjd15561-cit-0029","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1111\/bjd.15561-BIB0030|bjd15561-cit-0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hec.843","article-title":"Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data","volume":"13","author":"Willan","year":"2004","journal-title":"Health Econ"},{"key":"10.1111\/bjd.15561-BIB0031|bjd15561-cit-0031","unstructured":"National Institute for Health and Care Excellence Guide to the Methods of Technology Appraisal London NICE 2013 https:\/\/www.nice.org.uk\/process\/pmg9"},{"key":"10.1111\/bjd.15561-BIB0032|bjd15561-cit-0032","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(02)09832-X","article-title":"A rational framework for decision making by the National Institute for Clinical Excellence (NICE)","volume":"360","author":"Claxton","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/bjd.15561-BIB0033|bjd15561-cit-0033","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"10.1111\/bjd.15561-BIB0034|bjd15561-cit-0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19110","article-title":"Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme","volume":"19","author":"Raftery","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1111\/bjd.15561-BIB0035|bjd15561-cit-0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hec.1093","article-title":"Whither trial-based economic evaluation for health care decision making?","volume":"15","author":"Sculpher","year":"2006","journal-title":"Health Econ"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.15561\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T13:57:00Z","timestamp":1719151020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/177\/6\/1527\/6697342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15561","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5,31]]}}}